Release Date: 16-Jul-2024
Bafisontamab (EMB-01) is a groundbreaking cancer therapy with an innovative mechanism targeting EGFR and c-MET. Developed by Epimab using the FIT-Ig platform, it shares similarities with amivantamab. This bispecific antibody offers a potential first-in-class approach for solid tumors, presenting a unique mode of action unmatched by other drug classes. Bafisontamab marks a paradigm shift in cancer treatment, signaling promising prospects for the future of targeted therapies in addressing diverse solid tumors.
Bafisontamab uniquely targets and binds to both wild-type and mutant forms of EGFR and c-Met on cancer cells. This dual binding prevents receptor phosphorylation, effectively inhibiting EGFR- and c-Met-mediated signaling pathways. This leads to potent inhibition of tumor cell proliferation, crucial given the pivotal roles of EGFR and c-Met in this process. Bafisontamab’s design, featuring two antigen-binding fragments (Fabs) in a crisscross orientation, provides four active and independent antigen-binding sites. This enhances efficacy in disrupting crucial signaling pathways for tumor growth.
With its unique tetravalent binding, Bafisontamab preserves the full biological activity of the parental monoclonal antibody, blocking ligand binding and downstream signal pathways. Its exceptional synergistic function induces notable co-degradation of both EGFR and cMET in various tumor cells, an effect unattainable by monoclonal antibodies alone or in combination. Bafisontamab maintains efficacy in anti-EGFR monoclonal antibody-resistant tumor models, showcasing a distinct advantage. This ability to overcome resistance and induce co-degradation underscores Bafisontamab’s potential as a potent therapeutic option, demonstrating significant anti-tumor activity and addressing challenges posed by resistant tumor cells.
The potential advantages of Bafisontamab are evident in the treatment of EGFR and/or cMET-driven cancers, especially in instances where patients develop acquired resistance due to secondary EGFR mutations in the kinase domain or cMET activation. Ongoing phase I/II trials are assessing its efficacy in advanced EGFR-mutant lung cancer and gastrointestinal cancers. Initial results from the phase I trials indicate a manageable safety profile, showcasing the promising potential of Bafisontamab in the treatment of these challenging cancers.
In summary, Bafisontamab stands out as a promising innovation in cancer treatment, presenting a unique mechanism of action targeting EGFR and cMET. Its tetravalent binding feature demonstrates remarkable co-degradation of these receptors in various tumor cells, while clinical results suggest a manageable safety profile, highlighting its potential in treating solid tumors, particularly in cases of acquired resistance. Bafisontamab’s innovative approach positions it as a hopeful contender for reshaping cancer therapy, offering a distinct and effective strategy for the future treatment of solid cancers.
For Clinical Trials Information Contact